Suppr超能文献

HIV-1 包膜三聚体比单体 gp120 引发更强的中和抗体反应。

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

机构信息

Division of Molecular Medicine, Children's Hospital, Boston, MA 02115, USA.

出版信息

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12111-6. doi: 10.1073/pnas.1204533109. Epub 2012 Jul 5.

Abstract

HIV-1 envelope glycoprotein is the primary target for HIV-1-specific antibodies. The native HIV-1 envelope spike on the virion surface is a trimer, but trimeric gp140 and monomeric gp120 currently are believed to induce comparable immune responses. Indeed, most studies on the immunogenicity of HIV-1 envelope oligomers have revealed only marginal improvement over monomers. We report here that suitably prepared envelope trimers have nearly all the antigenic properties expected for native viral spikes. These stable, rigorously homogenous trimers have antigenic properties markedly different from those of monomeric gp120s derived from the same sequences, and they induce potent neutralizing antibody responses for a cross-clade set of tier 1 and tier 2 viruses with titers substantially higher than those elicited by the corresponding gp120 monomers. These results, which demonstrate that there are relevant immunologic differences between monomers and high-quality envelope trimers, have important implications for HIV-1 vaccine development.

摘要

HIV-1 包膜糖蛋白是 HIV-1 特异性抗体的主要靶标。病毒表面上天然的 HIV-1 包膜刺突是三聚体,但目前认为三聚体 gp140 和单体 gp120 可诱导相当的免疫反应。事实上,大多数关于 HIV-1 包膜寡聚体免疫原性的研究仅显示出与单体相比略有改善。我们在此报告称,经过适当制备的包膜三聚体具有几乎所有预期的天然病毒刺突的抗原特性。这些稳定、严格同质的三聚体具有与源自相同序列的单体 gp120 明显不同的抗原特性,并且它们诱导针对跨群 1 和 2 级病毒的强效中和抗体反应,其滴度明显高于相应 gp120 单体引起的滴度。这些结果表明单体和高质量包膜三聚体之间存在相关的免疫学差异,对 HIV-1 疫苗的开发具有重要意义。

相似文献

1
HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12111-6. doi: 10.1073/pnas.1204533109. Epub 2012 Jul 5.
2
Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
J Virol. 2018 May 29;92(12). doi: 10.1128/JVI.00277-18. Print 2018 Jun 15.
4
Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.
PLoS One. 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013.
5
Conformational States of a Soluble, Uncleaved HIV-1 Envelope Trimer.
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.00175-17. Print 2017 May 15.
6
Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.
J Biol Chem. 2017 Jan 6;292(1):278-291. doi: 10.1074/jbc.M116.725614. Epub 2016 Nov 22.

引用本文的文献

1
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.
NPJ Vaccines. 2024 Apr 6;9(1):74. doi: 10.1038/s41541-024-00862-8.
2
Microsecond dynamics control the HIV-1 Envelope conformation.
Sci Adv. 2024 Feb 2;10(5):eadj0396. doi: 10.1126/sciadv.adj0396.
3
Modulation of immune responses to liposomal vaccines by intrastructural help.
Eur J Pharm Biopharm. 2023 Nov;192:112-125. doi: 10.1016/j.ejpb.2023.10.003. Epub 2023 Oct 4.
6
Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120.
Cell Chem Biol. 2023 May 18;30(5):540-552.e6. doi: 10.1016/j.chembiol.2023.03.003. Epub 2023 Mar 22.
7
HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier.
Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2215792120. doi: 10.1073/pnas.2215792120. Epub 2023 Feb 16.
8
Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans.
AIDS Res Hum Retroviruses. 2023 Jul;39(7):350-366. doi: 10.1089/AID.2022.0104. Epub 2023 Mar 22.
10
Process development and preclinical evaluation of a major blood stage vaccine candidate, Cysteine-Rich Protective Antigen (CyRPA).
Front Immunol. 2022 Sep 22;13:1005332. doi: 10.3389/fimmu.2022.1005332. eCollection 2022.

本文引用的文献

2
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.
J Virol. 2012 Mar;86(5):2488-500. doi: 10.1128/JVI.06259-11. Epub 2011 Dec 28.
5
Antibody-based protection against HIV infection by vectored immunoprophylaxis.
Nature. 2011 Nov 30;481(7379):81-4. doi: 10.1038/nature10660.
6
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
Nature. 2011 Nov 23;480(7377):336-43. doi: 10.1038/nature10696.
7
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
Science. 2011 Nov 25;334(6059):1097-103. doi: 10.1126/science.1213256. Epub 2011 Oct 13.
8
Vaccinology: precisely tuned antibodies nab HIV.
Nature. 2011 Sep 21;477(7365):416-7. doi: 10.1038/477416a.
9
Broad neutralization coverage of HIV by multiple highly potent antibodies.
Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验